Pharm-Olam rescued this US-based study (from another CRO) that struggled to recruit 300 patients over 15 months. Pharm-Olam was able to recruit 197 patients from 12 sites in Poland in 2.5 months, allowing our sponsor to meet their enrollment target on time. The study drug later received NDA approval in pediatrics.
“The selection of Pharm-Olam was necessary due to the inability of other CROs to complete enrollment. The recruitment challenges were considerable based on the required age and inclusion/exclusion criteria. We asked Pharm-Olam to basically double their enrollment timelines half way through the trial and still meet the original timelines. The team successfully met this challenge.”